Oligonucleotide Therapy Market Size & Industry Outlook
The Oligonucleotide Therapy Market will reach US$ 12.38 billion in 2026, up from US$ 10.44 billion in 2025, and is projected to reach US$ 57.59 billion by 2035, registering robust growth at a CAGR of 18.6% during the forecast period from 2026 to 2035
The market is being driven by the rising demand for precision medicine and targeted genetic treatments. Advancements in antisense oligonucleotides (ASOs) and siRNA therapies have enabled effective treatment of rare genetic disorders, such as Spinraza for spinal muscular atrophy and Onpattro for hereditary transthyretin-mediated amyloidosis.
The increasing prevalence of neurodegenerative diseases, cancers, and cardiovascular disorders is pushing the adoption of these therapies. Additionally, ongoing R&D investments, favorable regulatory approvals, and the expansion of biopharmaceutical infrastructure in regions like North America and Asia-Pacific are accelerating market growth. Companies are also developing novel delivery systems and conjugates, such as antibody-oligonucleotide conjugates, to enhance efficacy and safety. This combination of unmet medical needs and technological innovation is positioning oligonucleotide therapies as a key component of the future of personalized medicine.
Key Takeaways
- North America accounts for approximately 40.27% of the global market share, driven by strong biotechnology investments, favorable regulatory approvals, and increasing commercialization of RNA-based therapeutics.
- Antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) therapies collectively contribute over 65% of total market revenue, owing to their proven efficacy in treating rare genetic, neurological, and metabolic disorders.
- Neurodegenerative disorders account for nearly 40.21% of total market demand, supported by the growing adoption of approved therapies for spinal muscular atrophy, amyotrophic lateral sclerosis (ALS), and hereditary transthyretin-mediated amyloidosis.
- Hospitals and specialty treatment centers collectively represent more than 55% of end-user adoption, leveraging advanced oligonucleotide therapies for personalized and targeted treatment approaches.
- RNA-based therapeutics are witnessing annual adoption growth exceeding 20%, fueled by advancements in delivery technologies, chemical modifications, and expanding clinical pipelines across multiple therapeutic areas.
- The Asia-Pacific region is projected to register a CAGR of approximately 17.9%, supported by increasing biotechnology investments, growing clinical trial activities, and expanding pharmaceutical manufacturing capabilities.
- AI-enabled oligonucleotide design platforms are increasingly accelerating drug discovery timelines, improving target identification, efficacy prediction, and personalized therapeutic development.
- Strategic collaborations among biotechnology companies, pharmaceutical manufacturers, and contract development and manufacturing organizations (CDMOs) are accelerating product commercialization globally.
- Growing investments in precision medicine, gene-targeted therapeutics, advanced delivery systems, and next-generation RNA technologies are expected to drive long-term market expansion.
Oligonucleotide Therapy Market Dynamics
Drivers:The rising prevalence of genetic and rare diseases is significantly driving the oligonucleotide therapy market growth
The rising prevalence of genetic and rare diseases is a significant driver of the oligonucleotide therapy market's growth. Rare diseases collectively affect approximately 3.5% to 5.9% of the global population, equating to over 400 million individuals worldwide. Notably, around 80% of these rare diseases have a genetic origin, and nearly 95% lack approved treatments. This substantial unmet medical need has spurred the development of targeted therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which can precisely modulate gene expression to treat these conditions.
For instance, Spinraza (nusinersen), an ASO, has been approved for spinal muscular atrophy, a rare genetic disorder. Similarly, Onpattro (patisiran), an siRNA therapy, addresses hereditary transthyretin-mediated amyloidosis, another rare genetic disease. These therapies exemplify the potential of oligonucleotide-based treatments to address previously untreatable conditions.
Restraints:Competition from alternative therapies is hampering the growth of the market
Competition from alternative therapies is a notable restraint on the growth of the oligonucleotide therapy market. Gene-editing technologies like CRISPR/Cas9 and TALENs offer the potential for permanent correction of genetic defects, which can be more attractive than oligonucleotide therapies that often require repeated administration. Similarly, monoclonal antibodies and small-molecule drugs are well-established, widely available, and often less expensive options for conditions such as cancers and autoimmune disorders, creating significant competition.
For instance, in oncology, monoclonal antibodies like Keytruda and small-molecule kinase inhibitors such as Imatinib are preferred for certain cancer types, limiting the adoption of oligonucleotide therapies. In rare genetic disorders, CRISPR-based therapies in clinical trials for sickle cell disease and beta-thalassemia promise potentially curative outcomes, whereas therapies like Spinraza require ongoing dosing.
For more details on this report – Request for Sample
Oligonucleotide Therapy Market Scope
| Metrics | Details | |
| CAGR | 18.6% | |
| Market Size Available for Years | 2023-2035 | |
| Estimation Forecast Period | 2026-2035 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Type | Antisense Oligonucleotides, Small Interfering RNA (siRNA), MicroRNA (miRNA), Aptamers, Ribozymes, and Others |
| Application | Oncology, Neurodegenerative Disorders, Infectious Diseases, Cardiovascular Diseases, Kidney Diseases, and Others | |
| End User | Hospitals, Academic and Research Institutes, and Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
Oligonucleotide Therapy Market Artificial Intelligence and Next-Generation Oligonucleotide Therapeutics Analysis
The Oligonucleotide Therapy Market is witnessing substantial technological transformation driven by advancements in RNA-targeted therapeutics, precision medicine initiatives, and next-generation nucleic acid technologies worldwide. Artificial intelligence-enabled drug discovery platforms, intelligent oligonucleotide design capabilities, predictive therapeutic analytics systems, and advanced bioinformatics technologies are substantially improving the development and commercialization of highly targeted oligonucleotide therapies across diverse disease applications globally. These innovations are enabling manufacturers to optimize target selection strategies, improve therapeutic specificity characteristics, and enhance delivery system capabilities while simultaneously addressing previously undruggable genetic targets across modern healthcare ecosystems.
Manufacturers are increasingly focusing on developing advanced oligonucleotide therapeutics encompassing antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA therapeutics, aptamers, and splice-switching oligonucleotides designed to improve therapeutic outcomes across rare genetic disorders, oncology, cardiovascular diseases, neurodegenerative conditions, and infectious diseases worldwide. Furthermore, increasing investments supporting RNA medicine technologies are anticipated to substantially strengthen commercialization opportunities throughout the forecast period.
Oligonucleotide Therapy Market Precision Medicine and Rare Disease Therapeutics Analysis
The accelerating adoption of precision medicine initiatives continues creating substantial growth opportunities across the global Oligonucleotide Therapy Market. Healthcare providers are increasingly utilizing RNA-targeted therapeutic technologies capable of selectively modulating disease-causing genes while simultaneously minimizing off-target effects across complex disease applications.
Oligonucleotide therapies continue representing attractive therapeutic solutions for rare genetic disorders owing to their highly targeted mechanisms of action and personalized treatment capabilities. The increasing commercialization of therapies targeting spinal muscular atrophy, hereditary transthyretin-mediated amyloidosis, Duchenne muscular dystrophy, and Huntington's disease is substantially strengthening global market demand. Furthermore, expanding clinical pipelines addressing previously untreatable diseases are anticipated to positively influence future market competitiveness considerably throughout the forecast period.
Growing emphasis on personalized medicine initiatives integrating genomic technologies and intelligent therapeutic platforms is expected to significantly strengthen commercialization opportunities across modern healthcare ecosystems worldwide.
Oligonucleotide Therapy Market RNA Therapeutics and Advanced Drug Delivery Analysis
RNA-targeted therapeutic technologies continue representing one of the fastest-growing segments across the global biotechnology industry. Advanced oligonucleotide therapies are increasingly demonstrating superior capabilities across gene silencing, splice modulation, and protein expression regulation applications worldwide.
Modern therapeutic development platforms increasingly incorporate intelligent drug delivery technologies involving lipid nanoparticles, GalNAc conjugates, antibody-oligonucleotide conjugates, and targeted tissue delivery systems designed to substantially improve therapeutic effectiveness and patient outcomes. Furthermore, advancements involving stereopure oligonucleotide technologies and precision delivery capabilities are anticipated to accelerate commercialization opportunities considerably across global healthcare markets.
The convergence between artificial intelligence-enabled therapeutic design capabilities and next-generation delivery technologies is expected to substantially strengthen future market competitiveness throughout the forecast period.
Oligonucleotide Therapy Market Regulatory Landscape and Healthcare Innovation Analysis
The regulatory landscape supporting oligonucleotide therapeutics continues evolving significantly across major healthcare economies worldwide. Regulatory organizations are increasingly implementing frameworks supporting accelerated approvals for innovative therapies addressing unmet medical needs while simultaneously strengthening patient safety initiatives globally.
Oligonucleotide therapies are increasingly benefiting from favorable regulatory pathways designed to support rare disease treatments and precision medicine innovations across developed healthcare markets. Growing investments supporting genomic medicine capabilities and translational research initiatives are substantially strengthening market adoption patterns across global healthcare ecosystems.
Furthermore, increasing governmental support for advanced biotechnology innovations and personalized therapeutic developments is anticipated to positively influence future commercialization opportunities considerably throughout the forecast period
Oligonucleotide Therapy Market Investment and Strategic Collaboration Analysis
Public and private sector investments supporting advanced oligonucleotide technologies continue creating substantial commercialization opportunities across global healthcare markets. Industry participants are increasingly allocating resources toward RNA therapeutic capabilities, intelligent drug development technologies, and next-generation nucleic acid innovations designed to improve clinical outcomes significantly.
Strategic collaborations involving pharmaceutical organizations, biotechnology companies, academic institutions, and artificial intelligence technology providers are substantially accelerating technological innovation activities worldwide. Organizations are increasingly pursuing partnerships supporting RNA-targeted therapeutic developments, precision medicine initiatives, and advanced drug delivery technologies globally.
Furthermore, increasing investments supporting biotechnology infrastructures and personalized healthcare capabilities are anticipated to substantially strengthen regional competitiveness throughout North America, Europe, and Asia-Pacific during the forecast period.
Oligonucleotide Therapy Market Emerging Technologies Analysis
Emerging technologies involving artificial intelligence-assisted oligonucleotide design platforms, intelligent therapeutic analytics systems, advanced nucleic acid delivery technologies, and personalized RNA medicine capabilities are substantially transforming future market opportunities worldwide. Innovations supporting enhanced target specificity characteristics, improved tissue delivery performances, and optimized therapeutic outcomes are anticipated to significantly strengthen market competitiveness across global healthcare applications.
Additionally, advanced computational biology capabilities supporting RNA therapeutic discoveries are expected to improve product development efficiencies while simultaneously strengthening commercialization opportunities globally. The convergence between intelligent biotechnology platforms and precision medicine paradigms will continue influencing future technological developments across the Oligonucleotide Therapy Market worldwide.
Oligonucleotide Therapy Market Future Market Trends (2026-2035)
The Oligonucleotide Therapy Market is expected to witness substantial growth throughout the forecast period driven by increasing adoption across precision medicine initiatives, RNA therapeutic innovations, intelligent biotechnology developments, and personalized healthcare programs worldwide. Future market expansion will be supported by next-generation delivery technologies, advanced nucleic acid capabilities, rare disease therapeutic developments, and intelligent drug discovery innovations across major global economies.
Increasing investments supporting biotechnology infrastructures, precision medicine ecosystems, and advanced therapeutic platforms are anticipated to substantially strengthen commercialization opportunities globally. Furthermore, growing demand for highly targeted and clinically effective therapeutic solutions capable of improving patient outcomes while simultaneously addressing unmet medical needs is expected to significantly influence future market dynamics through 2035.
Oligonucleotide Therapy Market Segment Analysis
The global oligonucleotide therapy market is segmented based on type, application, end-user, and region.
Application:The neurodegenerative disorders segment is dominating the oligonucleotide therapy market with a 40.21% share in 2025
The neurodegenerative disorders segment is currently the dominant force in the oligonucleotide therapy market, primarily due to the high unmet medical need, aging populations, and significant advancements in RNA-targeted therapeutics. This segment encompasses a variety of debilitating conditions, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease, all characterized by progressive neuronal degeneration and limited treatment options. Several approved therapies exemplify the transformative potential of oligonucleotides in this field.
For instance, Spinraza (nusinersen), approved in 2016, was the first FDA-approved therapy for SMA, functioning by modifying SMN2 gene splicing to produce functional SMN protein critical for motor neuron survival. Qalsody (tofersen), approved in April 2023, addresses ALS patients with SOD1 gene mutations by reducing the production of the toxic SOD1 protein, directly targeting the genetic cause of the disease. In December 2023, eplontersen (Wainua) received approval for hereditary transthyretin-mediated amyloidosis, an antisense oligonucleotide that reduces TTR protein accumulation in tissues. Additionally, Brineura (cerliponase alfa), approved in 2017, provides enzyme replacement for CLN2, a form of Batten disease, slowing progression in pediatric patients.
In April 2025, Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. These reflect regulatory encouragement for innovative RNA-targeted therapies.
The oncology segment is the fastest-growing segment in the oligonucleotide therapy market, with a 27.01% share in 2025
The oncology segment is currently the fastest-growing segment in the oligonucleotide therapy market, fueled by the rising global prevalence of cancer, rapid advancements in RNA-targeted therapeutics, and increased regulatory support for innovative treatments. The growth in this segment is evident from the significant rise in FDA approvals for RNA-based therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, which increased from 14 ASOs and 7 siRNAs in 2024 to 23 approved nucleic acid drugs by 2025.
A landmark approval in 2024 was Rytelo (imetelstat), an oligonucleotide telomerase inhibitor for myelodysplastic syndrome, demonstrating the clinical potential of oligonucleotides in hematologic cancers. Innovations in delivery technologies, such as antibody-oligonucleotide conjugates, have further enhanced specificity and efficacy, particularly in targeting solid tumors, overcoming previous limitations of RNA therapies.
Oligonucleotide Therapy Market Geographical Analysis
North America is expected to dominate the global oligonucleotide therapy market with a 40.27% in 2025
North America is the dominant region in the global oligonucleotide therapy market, driven by robust regulatory frameworks, substantial research and development investments, and a high concentration of leading pharmaceutical and biotech companies. Strong regulatory support, substantial financial backing, a concentration of innovative companies, advanced manufacturing infrastructure, and strategic collaborations collectively position North America as the leading region in the global oligonucleotide therapy market, enabling rapid adoption of therapies, expansion of clinical pipelines, and sustained market growth.
US Oligonucleotide Therapy Market Trends
The United States has been at the forefront of oligonucleotide-based drug approvals, with the FDA having approved 22 oligonucleotide therapies as of April 2025, providing strong regulatory support that facilitates the commercialization of innovative therapies. Notable approvals in recent years underscore this leadership, for instance, in August 2025, Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK).
Additionally, the region dominates the oligonucleotide contract development and manufacturing organization (CDMO) market, capturing a significant share in 2024, highlighting its capability in large-scale production and commercialization. Strategic partnerships and investments further reinforce this dominance; for instance, Avidity Biosciences, headquartered in San Diego, received FDA Breakthrough Therapy Designation for its lead program, delpacibart etedesiran, aimed at treating myotonic dystrophy type 1.
The Asia Pacific region is the fastest-growing region in the global oligonucleotide therapy market, with a CAGR of 17.9% in 2025
The Asia Pacific region is emerging as the fastest-growing market in the global oligonucleotide therapy sector, driven by substantial investments in biotechnology, expanding healthcare infrastructure, and increasing adoption of RNA-based therapeutics. The region’s growth is further bolstered by the increasing number of clinical trials and approvals for oligonucleotide therapies targeting rare genetic disorders, oncology, and neurodegenerative diseases. In addition, Asia Pacific is strengthening its position in oligonucleotide synthesis and contract development and manufacturing organization (CDMO) services, which are critical for large-scale production and commercialization.
With increasing awareness of personalized medicine, the adoption of oligonucleotide therapies is gaining traction among healthcare providers and patients, particularly in urban centers with advanced healthcare infrastructure. The combined effect of government incentives, strong manufacturing capabilities, and rising prevalence of target diseases is driving the Asia Pacific to become the fastest-growing region, making it a key focus area for global pharmaceutical companies seeking to expand their oligonucleotide therapy pipelines.
Europe Oligonucleotide Therapy Market Trends
Europe is experiencing significant growth in the oligonucleotide therapy market, driven by several key factors. The European Medicines Agency (EMA) has approved multiple oligonucleotide-based therapies, such as Qalsody (tofersen) for ALS and Spinraza (nusinersen) for spinal muscular atrophy, highlighting the region's commitment to advancing RNA-based treatments.
Additionally, the European Union's investment in synthetic biology and genomics is fostering an environment conducive to the development of personalized medicine. Collaborations between academic institutions and biotech companies are accelerating the discovery and commercialization of novel oligonucleotide therapies. Countries like Germany are leading this growth, supported by a robust healthcare infrastructure and a strong emphasis on research and development. These developments position Europe as a pivotal player in the global oligonucleotide therapy landscape.
Oligonucleotide Therapy Market Competitive Landscape
Top companies in the oligonucleotide therapy market include Sarepta Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Wave Life Sciences, Novartis AG, Biogen, Regeneron Pharmaceuticals Inc., and Avidity Biosciences, among others.
Recent Developments in Oligonucleotide Therapy Market
- June 2026: Sarepta Therapeutics, Inc. announced that the U.S. FDA accepted the supplemental New Drug Applications (sNDAs) for AMONDYS 45® and VYONDYS 53®, seeking conversion from accelerated to traditional approval for the treatment of Duchenne muscular dystrophy.
- June 2026: Alnylam Pharmaceuticals, Inc. continued advancing its RNAi therapeutics pipeline through ongoing late-stage clinical development programs targeting cardiometabolic, neurological, and rare genetic diseases.
- May 2026: Novartis AG expanded its oligonucleotide therapeutics research initiatives through continued investments in RNA-targeted medicines and precision medicine platforms across multiple disease areas.
- May 2026: Biogen Inc. strengthened its rare disease portfolio by advancing antisense oligonucleotide research programs focused on neurological disorders and neurodegenerative diseases.
- April 2026: Ionis Pharmaceuticals, Inc. progressed multiple antisense oligonucleotide candidates across neurology and cardiology indications, reinforcing its leadership in RNA-targeted therapeutics development.
- April 2026: Regeneron Pharmaceuticals, Inc. continued expanding its genetic medicines capabilities through investments in RNA-based therapeutics and strategic research collaborations supporting precision medicine approaches.
- March 2026: Wave Life Sciences Ltd. advanced its stereopure oligonucleotide platform with ongoing clinical programs targeting genetic diseases, strengthening its precision RNA medicines portfolio.
- March 2026: Avidity Biosciences, Inc. expanded the clinical development of its antibody oligonucleotide conjugate (AOC™) therapeutics for rare muscular disorders and precision genetic medicine applications.
- February 2026: Sarepta Therapeutics, Inc. received approval from New Zealand's Medsafe for the clinical trial application of SRP-1005, an investigational small interfering RNA (siRNA) therapy for Huntington's disease, with the first-in-human study expected to begin in the second quarter of 2026.
Who Should Buy This Report?
This report is designed for biopharmaceutical companies, biotechnology firms, oligonucleotide therapy developers, pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), hospitals and specialty treatment centers, clinical research organizations (CROs), academic and research institutions, healthcare technology providers, government healthcare agencies, institutional investors, private equity firms, healthcare consulting organizations, and market intelligence companies. It provides valuable insights for stakeholders seeking to identify growth opportunities, strengthen precision medicine strategies, evaluate investment prospects, and make informed business decisions across the global oligonucleotide therapy ecosystem.
Why Should You Buy This Report?
This report provides comprehensive market size estimates and forecasts through 2035, helping organizations identify high-growth opportunities across antisense oligonucleotides, siRNA therapeutics, precision medicine applications, and advanced drug delivery technologies. It delivers detailed analysis of market drivers, restraints, opportunities, and challenges, along with regional and country-level trends supporting strategic planning. The report offers competitive intelligence covering company strategies, partnerships, acquisitions, clinical developments, regulatory approvals, and technological innovations. It also analyzes emerging technologies including AI-enabled oligonucleotide design platforms, GalNAc conjugation technologies, lipid nanoparticle delivery systems, and personalized RNA therapeutics. Additionally, it supports investment planning, business expansion, competitive benchmarking, and market entry strategies while helping organizations capitalize on the rapidly evolving global oligonucleotide therapy industry.
The global oligonucleotide therapy market report delivers a detailed analysis with 56 key tables, more than 56 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more pharmaceuticals-related reports, please click here
